Annexon, Inc. Announces Virtual Investor Event for ARCHER II Phase 3 Program
Annexon, Inc. will host a virtual investor event on November 3, 2026, to discuss the design and patient population of its ARCHER II Phase 3 clinical trial.
Stocks · News reference
Annexon shares are trading higher after HC Wainwright & Co. raised its price target on the stock from $14 to $25.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Annexin Pharmaceuticals: Invitation for Investor Q&A with Redeye Analyst
Annexin Pharmaceuticals has provided an opportunity for investors to submit questions to a Redeye analyst regarding the company.
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday
Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.